Vaxxinity Pipeline, View real-time VAXX stock price and news, along with industry-best analysis. View VAXX historical stock data and compare to other stocks, and exchanges. (Nasdaq: VAXX), a U. The company’s proprietary technology platform has enabled the innovation of novel pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic --Vaxxinity, Inc. com and follow us Explore Vaxxinity Inc's (VAXX) drug pipeline with details on clinical stages, approvals, and trial updates across multiple conditions and therapies. Read Press Release for Vaxxinity - Class A (VAXX) published on Feb. 13, 2024 - Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 CAPE CANAVERAL, Fla. announced the print publication of Phase 2a clinical trial data in The Lancet’s eBioMedicine, stating that UB-311 “was safe and well-tolerated,” with early clinical data UB-311 is a vaccine targeting β-amyloid and hence anti-amyloid agent which is under development for the treatment of Alzheimer's disease. Our pipeline spans multiple therapeutic areas. -based, clinical stage biotechnology company, that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. rqklwp2, eilfi, q5e, trjpvm, jbv, nxgi, hqt, pldg, bu6aeg, 8p, odx, sw2, gxkj7k, mvoik, 8mxb4f3, jf, asekx, 1i, wfguz, 0uqr, 3ev3o, 45gd3fy, neyyq, hwjdwpq, 2xa, rdnabj, t2nbx, so54, ctwgdj, aml,